List of Excipients in Branded Drug FULPHILA

Fulphila Excipient Strategy and Commercial Opportunities in Pegfilgrastim Biosimilars

Last updated: September 24, 2026

Fulphila (pegfilgrastim-jmdb) is a U.S.-approved biosimilar to Neulasta (pegfilgrastim). Its commercial opportunity is driven by oncology supportive-care demand, payer substitution, hospital procurement, and delivery-device differentiation rather than by a novel excipient platform. The product uses a conventional protein-stabilization system containing acetate, polysorbate 20, sorbitol, and water for injection. The principal excipient opportunities are formulation robustness, supply-chain control, device compatibility, cold-chain reduction, and differentiated presentations.

What excipients are used in Fulphila?

Fulphila is supplied as a preservative-free, single-dose pegfilgrastim injection. The FDA prescribing information identifies the following inactive ingredients:

Component	Role in formulation
Acetate	Buffering and pH control
Polysorbate 20	Surfactant; limits interfacial adsorption and aggregation
Sorbitol	Tonicity adjustment and protein stabilization
Water for injection	Vehicle

Fulphila is supplied at 6 mg in 0.6 mL, with a target pH of approximately 4.0. The FDA label identifies the excipients qualitatively but does not disclose the concentration of each inactive ingredient. The product is administered subcutaneously and is intended for single use. It does not contain a preservative. [1]

This composition is consistent with a conventional liquid formulation for a PEGylated protein. The formulation must maintain pegfilgrastim potency, control aggregation and particles, preserve syringe compatibility, and support refrigerated storage through the labeled shelf life.

What does each Fulphila excipient contribute?

Acetate provides a low-pH buffer environment. Pegfilgrastim formulations are generally maintained under acidic conditions because pH affects protein charge, aggregation, chemical degradation, and adsorption to container surfaces.

Polysorbate 20 reduces adsorption at air-liquid and liquid-solid interfaces. This is important for a protein administered from a prefilled syringe, where contact with silicone oil, glass, elastomer components, and the needle pathway can generate particulate or aggregation risks.

Sorbitol contributes osmolality and can stabilize the protein against some forms of physical stress. It also supports an injectable tonicity profile without requiring a higher ionic strength that could affect protein stability.

Water for injection is the vehicle. Because the product is a biologic, control of endotoxin, bioburden, particles, and container-closure integrity is as important as excipient identity.

How does the Fulphila formulation compare with Neulasta?

Fulphila is required to be highly similar to the reference product, Neulasta, without clinically meaningful differences in safety, purity, and potency. The biosimilar standard does not require identical inactive-ingredient concentrations in every case, but formulation differences must be justified through analytical, stability, and clinical data where applicable. [2]

Attribute	Fulphila	Neulasta reference product
Active ingredient	Pegfilgrastim-jmdb	Pegfilgrastim
Regulatory category	Biosimilar under the 351(k) pathway	Reference biologic
Dosage form	Injection, single-dose prefilled syringe	Injection, prefilled syringe and other approved presentations
Strength	6 mg/0.6 mL	6 mg/0.6 mL
Key excipient classes	Acetate, polysorbate 20, sorbitol, water	Protein buffer, surfactant, tonicity/stabilization excipients
Preservative	None in the labeled single-dose presentation	Presentation-dependent
Administration	Subcutaneous	Subcutaneous
Interchangeability	Depends on the specific FDA approval and presentation	Reference product

The commercial implication is clear: an excipient change cannot be treated as a routine generic reformulation. For a biosimilar, even a change in surfactant grade, buffer concentration, or sugar-polyol level can affect aggregation, subvisible particles, oxidation, potency, immunogenicity risk, and comparability.

What excipient strategies can improve Fulphila economics?

The strongest opportunities are incremental rather than radical. A new formulation must preserve biosimilarity while improving manufacturing yield, stability, logistics, or administration.

Surfactant optimization

Polysorbate 20 is widely used in biologics, but it can undergo oxidation and hydrolysis. Degradation products may increase particle formation or interact with the protein. A supplier or biosimilar developer could pursue:

• Higher-purity polysorbate 20 grades
• Tighter control of peroxide and aldehyde impurities
• Improved analytical release methods
• Alternative surfactants, subject to comparability data
• Reduced surfactant concentration without compromising container compatibility

The commercial value is strongest when the change reduces batch failures, extends shelf life, or improves compatibility with an on-body delivery system.

A switch from polysorbate 20 to polysorbate 80, poloxamer, or another surfactant would require extensive development work. Such a change could alter protein conformation, particle profiles, and immunogenicity-related quality attributes. It would not be a low-risk substitution.

Buffer and pH optimization

Acetate is a conventional choice, but buffer identity and concentration affect:

• Protein aggregation
• Deamidation and oxidation
• Surface adsorption
• Syringe component compatibility
• Freeze-thaw tolerance
• Long-term refrigerated stability

A modest pH adjustment or buffer-strength change could create a meaningful stability benefit, but it would need to remain within a well-supported biosimilar comparability package. The commercial goal would be a larger manufacturing operating window rather than a new pharmacologic effect.

Sorbitol and tonicity control

Sorbitol supports tonicity and physical stability. Opportunities include optimizing its concentration to reduce injection discomfort, improve osmolality, or protect against agitation and transport stress.

Potential development targets include:

• Lower particulate formation after shipping
• Better stability during temporary temperature excursions
• Reduced viscosity
• Improved filling accuracy
• Compatibility with smaller-volume or higher-concentration presentations

The main constraint is that osmolality changes can affect patient tolerability and product comparability. A formulation that is more concentrated may reduce injection volume but could increase viscosity and injection force.

What formulations are protected or commercially differentiated?

Fulphila’s labeled composition is not, by itself, a strong commercial moat. The key barriers are the total formulation and process package, including:

• Protein concentration and PEGylation profile
• Buffer and pH range
• Surfactant type and purity
• Polyol concentration
• Container-closure system
• Silicone-oil exposure
• Filling process
• Storage conditions
• Shipping qualification
• Analytical control strategy

Prefilled syringe opportunities

The prefilled syringe is the primary commercial platform. Excipient strategy must be evaluated with:

• Glass or polymer syringe materials
• Silicone oil level and distribution
• Needle lubricant
• Tungsten residues from syringe manufacture
• Extractables and leachables
• Stopper compatibility
• Needle gauge and injection force

A formulation that performs well in a vial may not perform identically in a prefilled syringe. Interface exposure is greater, and the device introduces mechanical stress, contact surfaces, and particulate risks.

On-body injector opportunities

The pegfilgrastim market includes automated on-body delivery systems intended to administer the dose after chemotherapy. An on-body presentation can improve convenience and reduce the need for a return visit, but it creates new formulation requirements.

Key excipient-related development issues include:

• Viscosity at the required dose concentration
• Stability during device residence time
• Compatibility with adhesives and device materials
• Resistance to agitation and vibration
• Delivery through a narrow needle or cannula
• Temperature exposure during wearable use
• Low particle burden after device activation

A Fulphila-compatible on-body product could command commercial value through reduced administration burden, even if the underlying formulation remains conventional. The device and formulation would need to be developed as an integrated combination product.

When does Fulphila lose exclusivity?

Fulphila did not receive the same type of market exclusivity as a novel chemical drug. It entered the U.S. market through the biosimilar pathway after FDA approval in 2018. Its commercial protection depends primarily on biosimilar competition, reference-product patent barriers, manufacturing know-how, contracts, payer positioning, and device differentiation. [1, 3]

Biologics use the Purple Book for FDA reference-product and biosimilar information. They are not generally managed through the Orange Book listing system used for small-molecule drugs. Fulphila therefore should not be analyzed as an Orange Book product with a conventional Paragraph IV timetable. [4]

The reference product’s patent estate and litigation history affected early biosimilar entry. Once multiple pegfilgrastim biosimilars reached the market, the principal erosion mechanism became price competition and formulary substitution rather than a single patent-expiration event.

Are Paragraph IV challenges relevant to Fulphila?

Paragraph IV certifications are associated with abbreviated new drug applications for small-molecule generics under the Hatch-Waxman framework. Fulphila was approved under the Biologics Price Competition and Innovation Act pathway, not as an ANDA. Its relevant legal mechanisms included the statutory patent-information exchange and patent-litigation process associated with biosimilar applications, often called the patent dance.

The practical distinction matters:

Issue	Small-molecule generic	Fulphila biosimilar
Primary FDA pathway	ANDA	351(k) BLA
Patent database	Orange Book	Purple Book and reference-product patent disclosures
Typical challenge	Paragraph IV certification	BPCIA patent-information exchange and litigation
Active ingredient standard	Same active ingredient	Highly similar biological product
Formulation flexibility	Generally greater	Constrained by analytical and clinical comparability

What patent litigation affects pegfilgrastim biosimilars?

Pegfilgrastim biosimilar competition has involved disputes over reference-product patents, manufacturing processes, formulation claims, delivery systems, and regulatory timing. The applicable patent risk is not limited to the labeled excipients.

For Fulphila and competing pegfilgrastim products, due diligence should classify patents into four groups:

1. Composition patents: claims directed to pegfilgrastim, PEG structures, conjugation profiles, or related compositions.
2. Formulation patents: claims covering buffer systems, surfactants, stabilizers, pH, concentration, or liquid stability.
3. Manufacturing patents: claims covering recombinant production, purification, PEGylation, filtration, filling, and particle control.
4. Device and use patents: claims covering prefilled syringes, on-body delivery, timing of administration, and chemotherapy-support protocols.

Formulation changes can reduce infringement exposure in some cases, but they can also create new patent risk if a competitor has broad claims covering a particular excipient combination, concentration range, or stability profile.

Which companies challenge Fulphila commercially?

The competitive set includes biosimilar and follow-on pegfilgrastim products from major manufacturers and specialty biologics companies. U.S. competition has included products such as Ziextenzo (pegfilgrastim-bmez), Udenyca (pegfilgrastim-cbqv), Stimufend (pegfilgrastim-fpgk), Fylnetra (pegfilgrastim-pbbk), and other approved or marketed pegfilgrastim products, depending on the relevant time period and commercial status. FDA’s Purple Book is the controlling source for current approval and interchangeability status. [4]

Competition is based on:

• Net price and rebate terms
• Preferred payer status
• Wholesaler and specialty-distributor access
• Hospital contracting
• Interchangeability designation
• Administration device
• Inventory reliability
• Patient-support services
• Cold-chain performance
• Supply continuity

Excipient differentiation alone is unlikely to win formulary share. It becomes commercially relevant when it supports a measurable product advantage, such as fewer particles, longer shelf life, lower injection force, reduced wastage, or a more reliable wearable presentation.

What is the revenue exposure for Fulphila?

Fulphila revenue is generally not reported as a separately disclosed line item in public financial reporting. The product contributes to a broader biosimilars and oncology portfolio, making product-specific revenue, gross margin, and market share difficult to isolate from company filings.

The economic opportunity remains meaningful because pegfilgrastim is administered broadly in chemotherapy regimens where prophylaxis against febrile neutropenia is indicated. Revenue exposure depends on:

• Number of treated chemotherapy cycles
• Prophylaxis guidelines
• Biosimilar discount levels
• Payer and provider substitution
• Hospital acquisition cost
• Physician-administered versus home-use channels
• Competition from long-acting and short-acting G-CSF products
• Manufacturing capacity and product availability

A manufacturer with a lower-cost, stable formulation may improve margin even without increasing the list price. Excipient cost is usually a small portion of total product cost, but excipients influence yield, failure rates, shelf life, and logistics, which have a larger economic effect.

How strong is the Fulphila patent and formulation position?

Fulphila’s strongest protection is likely to come from the combined biologic manufacturing process, analytical know-how, regulatory dossier, supply chain, and commercial contracts rather than from the disclosed excipient list.

Strengths

• Established biosimilar regulatory pathway
• Conventional and well-understood excipient system
• Large clinical use base for pegfilgrastim
• Potential for hospital and payer contracting
• Opportunity to leverage prefilled-syringe manufacturing infrastructure

Vulnerabilities

• Multiple pegfilgrastim competitors
• Limited differentiation from a standard liquid formulation
• Price erosion after additional biosimilar launches
• Dependence on cold-chain distribution
• Device and container-closure complexity
• Need for continued control of protein aggregation and particles

A formulation patent based only on acetate, polysorbate 20, sorbitol, and water would face potential validity and freedom-to-operate challenges unless it includes a technically specific concentration range, stability result, process limitation, or device interaction that provides a defensible inventive step.

What commercial opportunities exist for Fulphila excipients?

The most actionable opportunities are:

Opportunity	Commercial rationale	Development burden
High-purity polysorbate 20	Reduces oxidation and particle risk	Moderate
Lower-surfactant formulation	May improve impurity profile and cost	High
Alternative surfactant	Could improve stability or device compatibility	High
Optimized sorbitol level	May improve tonicity and transport stability	Moderate
Reduced injection volume	Supports patient convenience and device use	High
Longer refrigerated shelf life	Lowers inventory and wastage	High
Excursion-tolerant formulation	Reduces cold-chain losses	High
On-body-compatible formulation	Enables differentiated administration	Very high
Low-silicone syringe system	Reduces particle and aggregation risk	High
Regional excipient sourcing	Improves supply resilience and cost	Moderate

The highest-value strategy is usually a controlled formulation and device program rather than a wholesale excipient replacement. A developer can capture commercial value by improving stability and usability while maintaining the analytical similarity required for a biosimilar.

What generic and biosimilar launch risks exist?

Fulphila faces biosimilar launch risks rather than conventional generic-launch risks. The main scenarios are:

1. Price-led erosion: Multiple pegfilgrastim products compete for payer and hospital preference.
2. Interchangeability-led substitution: A product with an interchangeable designation may gain pharmacy-level substitution advantages where permitted.
3. Device-led differentiation: An on-body injector or lower-force presentation may protect net pricing.
4. Supply-led switching: Shortages or manufacturing interruptions can move accounts to competitors.
5. Patent or regulatory delay: Litigation, manufacturing supplements, or inspection findings can affect launch timing.
6. Channel fragmentation: Oncology practices, hospitals, specialty pharmacies, and home-injection channels may adopt different products.

Key Takeaways

• Fulphila contains acetate, polysorbate 20, sorbitol, and water for injection in a preservative-free single-dose presentation.
• The FDA label does not disclose the quantitative concentration of each excipient.
• Excipient innovation is constrained by the biosimilar comparability standard.
• Polysorbate purity, surfactant degradation, sorbitol optimization, and container compatibility are the most relevant formulation priorities.
• The product is governed by the biologics framework and Purple Book, not the conventional Orange Book Paragraph IV model.
• Fulphila’s commercial protection depends more on manufacturing, supply, contracting, device performance, and payer access than on the disclosed excipient list.
• The strongest commercial opportunity is an improved stability and delivery platform that preserves biosimilarity.
• A wearable or on-body presentation could create greater differentiation than a simple excipient substitution.
• Product-specific Fulphila revenue is generally not separately disclosed in public company reporting.
• Patent diligence should cover formulation, manufacturing, PEGylation, container closure, delivery devices, and methods of use.

FAQs

Can Fulphila use a different surfactant from polysorbate 20?

Potentially, but the change would require analytical and regulatory comparability support. A different surfactant could change aggregation, particles, potency, stability, and immunogenicity-related quality attributes.

Is sorbitol in Fulphila an active ingredient?

No. Sorbitol is an inactive ingredient used primarily for tonicity adjustment and protein stabilization.

Does Fulphila have an Orange Book patent listing?

Fulphila is a biologic approved under the 351(k) biosimilar pathway. Its regulatory and patent analysis is centered on the Purple Book and BPCIA-related patent procedures rather than a conventional Orange Book listing.

Can an excipient supplier patent a better Fulphila formulation?

Yes. A supplier or product developer could seek claims covering a specific excipient concentration range, impurity profile, stability result, container system, or manufacturing process. Patent strength would depend on novelty, nonobviousness, written description, enablement, and freedom from earlier disclosures.

What is the most valuable formulation improvement for Fulphila?

A formulation that supports longer shelf life, lower particulate formation, reduced injection force, or reliable operation in an on-body injector is likely to have greater commercial value than a small reduction in excipient cost.

References

1. U.S. Food and Drug Administration. (2018). Fulphila (pegfilgrastim-jmdb) prescribing information.
2. U.S. Food and Drug Administration. (2015). Scientific considerations in demonstrating biosimilarity to a reference product: Guidance for industry.
3. U.S. Food and Drug Administration. (2024). Biosimilar and interchangeable biosimilar biological products.
4. U.S. Food and Drug Administration. (2024). Purple Book: Database of licensed biological products.